Company news
Cue Biopharma, Inc. news in 2022
Cue Biopharma, Inc.'s news releases, calls and decks from 2022, newest first.
Cue Biopharma Reports Third Quarter 2022 Financial Results
November 13, 2022
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
November 13, 2022
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 9, 2022
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 4, 2022
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
October 3, 2022
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers
August 21, 2022
Cue Biopharma Reports Second Quarter 2022 Financial Results
August 3, 2022
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers
May 10, 2022
Cue Biopharma Reports First Quarter 2022 Financial Results
May 9, 2022
Cue Biopharma Reports Two Objective Responses (1 cPR and 1uPR) in First Interim Update from Dose Escalation Portion of Ongoing Phase 1 Combination Study of CUE-101 and KEYTRUDA® in First Line Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
January 25, 2022
Cue Biopharma to Host Business Update Call and Webcast for Ongoing CUE-101 Clinical Trials
January 19, 2022
Cue Biopharma and LG Chem Life Sciences Announce Development Milestone in Immuno-STAT Biologics Collaboration for CUE-102
January 4, 2022
Calls in 2022
Decks in 2022
- Q2 2022 Earnings Presentation
Earnings · 19 slides · Aug 23, 2022
- Investor Presentation (March 2022)
Investor deck · 22 slides · March 2022